Ivermectin, 'Wonder drug' from Japan: the human use perspective

Omura, S. and Crump, A., 2005, Nat. Rev. Microbiol., 2, 984, 10.1038/nrmicro1048

Omura, S., 2008, Int. J. Antimicrob. Agents, 31, 91, 10.1016/j.ijantimicag.2007.08.023

3) Campbell, W.C. (1992) The genesis of the antiparasitic drug ivermectin. <i>In</i> Inventive Minds (eds. Weber, R.J. and Perkins, D.N.). Oxford University Press, New York, pp. 194&ndash;214.

4) Frost, L., Reich, M.R. and Fujisaki, T. (2002) A partnership for ivermectin: Social Worlds and Boundary Objects. <i>In</i> Public-Private: Partnerships for Public Health (ed. Reich, M.R.). Harvard University Press, Cambridge, Mass., pp. 87&ndash;114.

5) Tavis, L.A. (1997) River Blindness: The Merck Decision to Develop and Donate MECTIZAN. <i>In</i> Power and Responsibility: Multinational Managers and Developing Country Concerns. University of Notre Dame Press, Indiana, pp. 87&ndash;113.

Thylefors, B., 2008, Ann. Trop. Med. Parasitol., 102, 39, 10.1179/136485908X337481

1979, Antimicrob. Agents Chemother., 15, 361, 10.1128/AAC.15.3.361

1979, Antimicrob. Agents Chemother., 15, 368, 10.1128/AAC.15.3.368

1979, Antimicrob. Agents Chemother., 15, 372, 10.1128/AAC.15.3.372

10.1021/jm00184a014

10.1126/science.6308762

12) Burg, R.W. and Stapley, E.O. (1989) Isolation and characterization of the producing organism. <i>In</i> Ivermectin and Abamectin (ed. Campbell, W.C.). Springer, New York, pp. 24&ndash;32.

13) Grisi, L., Massard, C.L., Moya-Borja, G.E. and Pereira, J.B. (2002) Impacto econ&ocirc;mico das principais ectoparasitoses em bovinos no Brasil. Hora Veterin&aacute;ria <b>21</b>, 8&ndash;10.

14) Ottesen, E. and Campbell, W. (1994) Ivermectin in human medicine. J. Antimicrob. Chemother. <b>34</b>, 195&ndash;203.

Eckholm, E., 1989, N.Y. Times Mag., 20

16) UNESCO (2005) World Science Report (2005) UNESCO, Paris, p. 198.

17) WHO (2010) Onchocerciasis (http://www.who.int/topics/onchocerciasis/en/).

10.1126/science.2218502

19) WHO (1995) Onchocerciasis and its control. Report of a WHO Expert Committee on Onchocerciasis Control Technical Report Series, No. 852 World Health Organization, Geneva, pp. 1--110.

20) WHO/TDR (1995) Tropical Disease Research: Progress 1975&ndash;94. WHO, Geneva, p. 95.

21) Denham, D.A. and Barrett, J. (1987) The chemotherapy of filarial nematode infections of man: aspirations and problems. <i>In</i> Chemotherapy of Tropical Diseases: The problem and the challenge (ed. Hooper, M.). John Wiley &amp; Sons. Ltd., pp. 45&ndash;68.

Duke, B.O., 1962, Trans. R. Soc. Trop. Med. Hyg., 56, 271

Duke, B.O., 1977, Tropenmed. Parasitol., 28, 447

24) Fujisaki, T. and Reich, M. (1998) TDR&rsquo;s contribution to the development of ivermectin for onchocerciasis. TDR, Geneva (TDR/ER/RD/98.3).

25) WHO/TDR (1976) Participation of the Pharmaceutical sector (TDR/WP/76.30).

26) Lucas, A.O. (2002) Public-private partnerships: illustrative examples. <i>In</i> Public-Private Partnerships for Public Health (ed. Reich M.). Harvard University Press, Cambridge, Mass., pp. 19&ndash;39.

10.1146/annurev.micro.45.1.445

28) Sturchio, J.L. (1992) The Decision to Donate Mectizan: Historical Background. Merck &amp; Co., Inc. Rahway, New Jersey, USA (unpublished document).

1982, Lancet, 2, 171

Coulaud, J.P., Larivi&egrave;re, 1983, Bull. Soc. Pathol. Exot. Filiales, 76, 681

31) Telex from Robert D. Fluss of Merck &amp; Co. Inc&rsquo;s Division of International Public Affairs sent to the Director of WHO/TDR, Dr Adetokunbo Lucas, on 20 June, 1986.

32) Campbell, W.C. (2010) History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents. <i>In</i> The Chemotherapy of Parasitic Diseases: Macrocyclic Lactones. Curr. Pharm. Biotechnol. <b>11</b> (In press).

Awadzi, K., 1980, Ann. Trop. Med. Parasitol., 74, 189, 10.1080/00034983.1980.11687330

Dadzie, K.Y., Bird, A.C., Awadzi, K, 1987, Br. J. Ophthalmol., 71, 78, 10.1136/bjo.71.2.78

Larivi&egrave;re, M., Aziz, M.,, 1985, Lancet, 326, 174, 10.1016/S0140-6736(85)91496-5

Diallo, S., Aziz, M.A., Ndir, O., B, 1987, Lancet, 1030, 10.1016/S0140-6736(87)92291-4

Kumaraswami, V., Ottesen, E.A. and, 1988, JAMA, 259, 3150, 10.1001/jama.259.21.3150

Ottesen, E.A., Kumaraswami, V. and, 1990, N. Engl. J. Med., 322, 1113, 10.1056/NEJM199004193221604

39) Richards, F.O. Jr., Eberhard, M.L., Bryan, R.T., Mcneeley, D.F., Lammie, P.J., Mcneeley, M.B., Bernard, Y., Hightower, A.W. and Spencer, H.C. (1991) Comparison of high-dose ivermectin and diethylcarbamazine for activity against Bancroftian filariasis in Haiti. Am. J. Trop. Med. Hyg. <b>44</b>, 3&ndash;10.

40) WHO (1997) World Health Assembly Resolution WHA 50.29 (http://www.who.int/lymphatic_filariasis/resources/WHA_50%2029.pdf).

41) Turner, M. and Schaeffer, J.M. (1989) Mode of action of ivermectin. <i>In</i> Ivermectin and Avermectin (ed. Campbell, W.). Springer-verlag, New York, pp. 73&ndash;88.

Campbell, W.C., 1985, Parasitol. Today, 1, 10, 10.1016/0169-4758(85)90100-0

43) Omura, S. (2002) Mode of action of avermectin. <i>In</i> Macrolide antibiotics; Chemistry, Biology &amp; Practice (2nd Edition) (ed. Omura, S.). Academic Press, San Diego, pp. 571&ndash;575.

del Mar Saez-De-Ocariz, M., McKinst, 2002, Clin. Exp. Dermatol., 27, 264, 10.1046/j.1365-2230.2002.01050.x

Maizels, R.M. and Lawrence, R.A., 1991, Parasitol. Today, 7, 271, 10.1016/0169-4758(91)90093-4

46) Taylor, H.R. and Greene, B.M. (1989) The status of ivermectin in the treatment of human onchocerciasis. Am. J. Trop. Med. Hyg. <b>41</b>, 460&ndash;466.

Plaisier, A.P., Alley, E.S., Boatin, 1995, J. Infect. Dis., 172, 204, 10.1093/infdis/172.1.204

Bas&aacute;&ntilde;ez, M.-G, 2008, Lancet Infect. Dis., 8, 310, 10.1016/S1473-3099(08)70099-9

Duke, B.O., Soula, G., Zea-Flores,, 1991, Trop. Med. Parasitol., 42, 25

10.1186/1475-2883-2-S1-S5

10.1073/pnas.1011983107

Allen, J.E., Adjei, O., Bain, O., H, 2008, PLoS Negl. Trop. Dis., 2, e217, 10.1371/journal.pntd.0000217

Kaplan, R.M., 2004, Trends Parasitol., 20, 477, 10.1016/j.pt.2004.08.001

10.1073/pnas.97.6.2674

Wolstenholme, A.J., 2004, Trends Parasitol., 20, 469, 10.1016/j.pt.2004.07.010

Lustigman, S. and McCarter, J.P., 2007, PLoS Negl. Trop. Dis., 1, e76, 10.1371/journal.pntd.0000076

57) Omura, S. and Crump, A. (2009) Community-directed intervention: replicating Japan&rsquo;s health successes in Africa? <i>In</i> Innovating for the health of all. Global Forum Update on Research for Health (6), Global Forum for Health Research, Geneva, pp. 87&ndash;90.

10.1016/j.pt.2005.08.014

dos Santos, A.R., Falc&atilde;o, 2009, Bioorg. Med. Chem., 17, 496, 10.1016/j.bmc.2008.12.003

Pitterna, T., Cassayre, J., H&u, 2009, Bioorg. Med. Chem., 17, 4085, 10.1016/j.bmc.2008.12.069

Moncayo, A.L., Vaca, M., Amorim, L., 2008, PLoS Negl. Trop. Dis., 2, e293, 10.1371/journal.pntd.0000293

Dunne, C.L., Malone, C.J. and Whitw, 1991, Trans. R. Soc. Trop. Med. Hyg., 85, 550, 10.1016/0035-9203(91)90255-W

Bockarie, M.J., Alexander, N.D., Ka, 2000, Acta Trop., 75, 127, 10.1016/S0001-706X(99)00087-X

Albonico, M., Crompton, D.W. and Sa, 1999, Adv. Parasitol., 42, 277, 10.1016/S0065-308X(08)60151-7

Heukelbach, J., 2004, Lancet, 363, 889, 10.1016/S0140-6736(04)15738-3

66) Heukelbach, J., Winter, B., Wilcke, T., Muehlen, M., Albrecht, S., de Oliviera, F.A., Kerr-Pontes, L.R., Liesenfeld, O. and Feldmeier, H. (2004) Selective mass treatment with ivermectin to control intestinal helminthiasis and parasitic skin diseases in a severely affected population. Bull. World Health Organ. <b>82</b> (8), 559&ndash;636.

2010, Nat. Rev. Microbiol., 8, 244, 10.1038/nrmicro2345

68) Speare, R. and Durrheim, D. (2004) Mass treatment with ivermectin: an underutilized public health strategy. Bull. World Health Organ. <b>82</b> (8), 559&ndash;636.